Literature DB >> 27073182

Low incidence of chronic GVHD after HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in older patients.

Raynier Devillier1,2, Angela Granata1, Sabine Fürst1, Samia Harbi1, Catherine Faucher1, Pierre-Jean Weiller1,2, Christian Chabannon2,3, Luca Castagna1,4, Didier Blaise1,2.   

Abstract

Entities:  

Keywords:  allogeneic transplantation; haploidentical transplantation; non-myeloablative conditioning regimen; older patients; post-transplantation cyclophosphamide

Mesh：

Substances：

Year:  2016        PMID： 27073182     DOI： 10.1111/bjh.13923

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

1.  Chronic Graft-versus-Host Disease: A Long Road Ahead.

Authors:  Sarah Anand; Stefanie Sarantopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2018-01-17       Impact factor: 5.742

Review 2.  Mechanistic approaches for the prevention and treatment of chronic GVHD.

Authors:  Corey S Cutler; John Koreth; Jerome Ritz
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

3.  CD56bright natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-versus-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results.

Authors:  Amina Kariminia; Sabine Ivison; Bernard Ng; Jacob Rozmus; Susanna Sung; Avani Varshney; Mahmoud Aljurf; Sylvie Lachance; Irwin Walker; Cindy Toze; Jeff Lipton; Stephanie J Lee; Jeff Szer; Richard Doocey; Ian Lewis; Clayton Smith; Naeem Chaudhri; Megan K Levings; Raewyn Broady; Gerald Devins; David Szwajcer; Ronan Foley; Sara Mostafavi; Steven Pavletic; Donna A Wall; Stephan Couban; Tony Panzarella; Kirk R Schultz
Journal:  Haematologica       Date:  2017-09-21       Impact factor: 9.941

4.  Clinical outcome of FLAG-IDA chemotherapy sequential with Flu-Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes.

Authors:  Ling Wang; Raynier Devillier; Ming Wan; Justine Decroocq; Liang Tian; Sabine Fürst; Li-Ning Wang; Norbert Vey; Xing Fan; Didier Blaise; Jiong Hu
Journal:  Bone Marrow Transplant       Date:  2018-08-06       Impact factor: 5.483
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.